Brief: Vertex Pharmaceuticals Q4 Adjusted EPS USD 5.03 Vs. IBES Estimate USD 5.07
12/02/2026 21:01
Feb 12 (Reuters) - Vertex Pharmaceuticals Q4 EPS USD 4.65. Q4 adjusted net income USD 1,300 million vs. IBES estimate USD 1,314 million
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31